Berkshire Hathaway’s Taylor Morrison Acquisition Signals Long-Term Housing Market View
Berkshire Hathaway's $6.8 billion acquisition of homebuilder Taylor Morrison Home indicates a long-term view on the U.S. housing market.
Investor topic hub
Markets
Market-moving news across stocks, bonds, currencies, private credit, capital markets, and investor sentiment.
Yield moves and rate-sensitive assets
Equity leadership and sector rotation
Liquidity, credit spreads, and risk appetite
Ulta Beauty Exceeds Q1 Expectations, Raises Full-Year Earnings Outlook
Ulta Beauty reported strong fiscal first-quarter results, beating analyst expectations for earnings and revenue.
Goldman Sachs CEO David Solomon: Markets in “Greed” Mode Amid AI IPO Wave
Goldman Sachs CEO David Solomon indicates markets are in a "greed" phase, with significant liquidity supporting an unprecedented wave of AI company fundraising, including...
Victoria’s Secret Shares Soar 40% Following Strong Q1 Earnings and Raised Outlook
Victoria's Secret exceeded Q1 2026 earnings expectations, reporting double the consensus EPS.
California’s Exodus Fuels Florida ‘Gold Rush’ Amid Economic Strain and Wealth Migration
California's economic challenges, including high taxes and costs, are prompting a significant exodus of wealthy residents and businesses, leading to a 'gold rush' in...
Ferrari’s First EV, the Luce, Sparks Backlash Over Design and Identity
Ferrari's first electric vehicle, the Luce, has sparked controversy.
Warner Music Group Taps Into Growing South Asian Music Scene with 5 Junction Venture
Warner Music Group's 5 Junction venture is investing in South Asian talent in the U.S.
Universal Music Group Rejects Bill Ackman’s $64.3 Billion Takeover Bid
Universal Music Group has rejected Bill Ackman's $64.3 billion takeover bid, citing that the offer fundamentally undervalues the music giant.
529 Plans Evolve as Powerful Savings Tools for College and Trade School Expenses
529 plans offer tax-free growth for college and trade school expenses, with expanded uses for K-12 tuition.
Replimune to Resubmit Melanoma Drug After FDA Leadership Change
Replimune is resubmitting its melanoma drug to the FDA for approval after two rejections, following a leadership change at the agency.